Sernova Corp. is a clinical stage regenerative medicine company developing cell therapy based medical technologies for the treatment of chronic debilitating diseases such as diabetes, blood disorders including hemophilia and other diseases all of which are treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch TM , a scalable, implantable medical device which forms a vascularized organ like environment for the transplantation of its locally immune protected therapeutic cells self cells, donor cells, ethically sourced stem cell derived therapeutic cells or xenogeneic cells which then release proteins and/or hormones as required by the body. The objective of the company s products is to disrupt the standard of care treatments for these serious diseases to improve efficacy, significantly improve patient quality of life and to decrease the severe debilitating disease effects that progress with the standard of care treatments. The product to treat diabetes involves implantation of a small biocompatible medical device under the skin into which are placed immune protected cells which connect to the blood vessel supply to read blood sugar levels and release insulin accordingly, replacing the metabolic function of the pancreas. For hemophelia the cells would release the required protein, Factor VIII on a constant basis reducing or eliminating the need for frequent infusions of Factor VIII.
Quote | Sernova Corp (OTCMKTS:SEOVF)
Last: | $0.2539 |
---|---|
Change Percent: | 0.0% |
Open: | $0.2539 |
Close: | $0.2539 |
High: | $0.2539 |
Low: | $0.229 |
Volume: | 6,500 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Sernova Corp (OTCMKTS:SEOVF)
(TheNewswire) To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non- diabetic range (HbA1c 6.5%); 6 patients have reached between 5.5 and 50 months o...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – June 12, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatmen...
Message Board Posts | Sernova Corp (OTCMKTS:SEOVF)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $SEOVF News Article - Sernova Announces Research Collaboration with AstraZeneca to Eval | whytestocks | investorshangout | 05/03/2023 6:45:49 PM |
Not sure what impact this will have: | KeepOn | investorshub | 04/15/2023 2:35:24 AM |
whytestocks: $SEOVF News Article - Sernova Announces Advancements with its Novel Cell Pouch System(T | whytestocks | investorshangout | 01/30/2023 4:45:44 PM |
Me 2 | Dr Martin VanNostrand | investorshub | 01/10/2023 12:22:26 PM |
whytestocks: $SEOVF News Article - The Principal Investigator in Sernova's Type 1 Diabetes (T1D) Tri | whytestocks | investorshangout | 01/10/2022 1:10:50 PM |
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non- diabetic range (HbA1c 6.5%); 6 patients have reached between 5.5 and 50 months o...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – June 12, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatmen...
Orbital Infrastructure Group Inc. (OIGBQ) is expected to report for Q1 2024 OFS Credit Company Inc. (OCCI) is expected to report for Q2 2024 KBC Groupe NV ADR (KBCSY) is expected to report for Q1 2024 Daikin Industries Ltd ADR (DKILY) is expected to report $0.11 for Q4 2024 Invita...